Log in

Relevant bibliographies by topics / CD8-Positive T-Lymphocytes Immunotherapy

Contents

Journal articles
Dissertations / Theses

Academic literature on the topic 'CD8-Positive T-Lymphocytes Immunotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CD8-Positive T-Lymphocytes Immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CD8-Positive T-Lymphocytes Immunotherapy"

1

Ruan, S., D. R. Samuelson, B. Assouline, M. Morre, and J. E. Shellito. "Treatment with Interleukin-7 Restores Host Defense against Pneumocystis in CD4+T-Lymphocyte-Depleted Mice." Infection and Immunity 84, no. 1 (2015): 108–19. http://dx.doi.org/10.1128/iai.01189-15.

Full text

Abstract:

Pneumocystispneumonia (PCP) is a major cause of morbidity and mortality in patients with HIV infection. CD4+T lymphocytes are critical for host defense against this infection, but in the absence of CD4+T lymphocytes, CD8+T lymphocytes may provide limited host defense. The cytokine interleukin-7 (IL-7) functions to enhance lymphocyte proliferation, survival, and recruitment of immune cells to sites of infection. However, there is little known about the role of IL-7 in PCP or its potential use as an immunotherapeutic agent. We hypothesized that treatment with recombinant human IL-7 (rhIL-7) woul

APA, Harvard, Vancouver, ISO, and other styles

2

Whiteside, TL, EM Elder, D. Moody, et al. "Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus." Blood 81, no. 8 (1993): 2085–92. http://dx.doi.org/10.1182/blood.v81.8.2085.2085.

Full text

Abstract:

Abstract Cytolytic T lymphocytes play an important role in host defense against viral infections, including human immunodeficiency virus (HIV). In a phase I clinical trial (protocol 080 of the AIDS Clinical Trials Group), generation of CD8+ effector cells from peripheral blood of patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC) or AIDS and safety of autologous adoptive transfer of these cells were evaluated. For therapeutic infusions, CD8+ T cells were purified by positive selection on anti-CD8 monoclonal antibody-coated flasks from leukapheresed peripheral blood o

APA, Harvard, Vancouver, ISO, and other styles

3

Whiteside, TL, EM Elder, D. Moody, et al. "Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus." Blood 81, no. 8 (1993): 2085–92. http://dx.doi.org/10.1182/blood.v81.8.2085.bloodjournal8182085.

Full text

Abstract:

Cytolytic T lymphocytes play an important role in host defense against viral infections, including human immunodeficiency virus (HIV). In a phase I clinical trial (protocol 080 of the AIDS Clinical Trials Group), generation of CD8+ effector cells from peripheral blood of patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC) or AIDS and safety of autologous adoptive transfer of these cells were evaluated. For therapeutic infusions, CD8+ T cells were purified by positive selection on anti-CD8 monoclonal antibody-coated flasks from leukapheresed peripheral blood of seven p

APA, Harvard, Vancouver, ISO, and other styles

4

Nishimura, Toshinobu, Shin Kaneko, Yoko Tajima, et al. "In Vitro Generation of Mature T Lymphocytes From Human Ips Cells and Genetic Analysis of TCR Gene Rearrangements." Blood 118, no. 21 (2011): 2984. http://dx.doi.org/10.1182/blood.v118.21.2984.2984.

Full text

Abstract:

Abstract Abstract 2984 T lymphocytes play central roles in cellular immunity, exerting their proliferative and effector activities when they recognize antigens via T-cell receptors (TCRs) in HLA-restricted and antigen-specific manner. Adoptive cell transfer therapy (ACT), the administration of ex vivo-activated and -expanded autologous tumor-reactive T lymphocytes, is currently one of the effective methods for immunotherapy, especially for treatment of metastatic solid tumors including melanoma. However, the successful applications of this method are currently limited for tumor therapies. To b

APA, Harvard, Vancouver, ISO, and other styles

5

Yee, Cassian, John A. Thompson, Patrick Roche, et al. "Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma." Journal of Experimental Medicine 192, no. 11 (2000): 1637–44. http://dx.doi.org/10.1084/jem.192.11.1637.

Full text

Abstract:

Current strategies for the immunotherapy of melanoma include augmentation of the immune response to tumor antigens represented by melanosomal proteins such as tyrosinase, gp100, and MART-1. The possibility that intentional targeting of tumor antigens representing normal proteins can result in autoimmune toxicity has been postulated but never demonstrated previously in humans. In this study, we describe a patient with metastatic melanoma who developed inflammatory lesions circumscribing pigmented areas of skin after an infusion of MART-1–specific CD8+ T cell clones. Analysis of the infiltrating

APA, Harvard, Vancouver, ISO, and other styles

6

Sharma, P., E. Sato, D. Bajorin, et al. "CD8+ tumor-infiltrating lymphocytes as a statistically significant marker of disease recurrence and survival in transitional cell carcinoma patients." Journal of Clinical Oncology 24, no. 18_suppl (2006): 4544. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.4544.

Full text

Abstract:

4544 Background: Superficial transitional cell carcinoma (TCC) is an immune-responsive tumor evidenced by immunotherapy trials with BCG demonstrating improved survival. In contrast, more advanced muscle-invasive TCC is not considered an immunologically active tumor. Yet, host immune functions that may have a clinical impact on the biologic activity of these more invasive tumors have not been systemically evaluated. CD8+ T-cells are responsible for cytotoxicity and potential tumor eradication by interaction with antigen plus human leukocyte antigens (HLA). A clear association between intratumor

APA, Harvard, Vancouver, ISO, and other styles

7

Yasukawa, Masaki, Hironari Niiya, Taichi Azuma, et al. "Generation of Tumor-Specific CD8+ Cytotoxic T Lymphocytes and CD4+ Th1 Helper T Cells by Transfer of T-Cell Receptor Genes Isolated from a WT1-Specific CD8+ Cytotoxic T-Lymphocyte Clone." Blood 104, no. 11 (2004): 2523. http://dx.doi.org/10.1182/blood.v104.11.2523.2523.

Full text

Abstract:

Abstract Background: Cytotoxic T lymphocytes (CTLs) and T-helper type 1 (Th1) cells undoubtedly play a crucial role in the eradication of tumors in vivo. However, the production of Th1 cytokines such as IL-2 and IFN-γ is markedly suppressed in the majority of tumor-bearing hosts. Such defects in Th1-mediated immunity in cancer patients have made it difficult to induce tumor-specific CTLs that promote tumor rejection. Adoptive transfer of tumor-specific CTLs and Th1 cells can overcome the difficulty to induce tumor-specific immune response in cancer patients; however, the generation and expansi

APA, Harvard, Vancouver, ISO, and other styles

8

Ohminami, Hideki, Masaki Yasukawa, and Shigeru Fujita. "HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide." Blood 95, no. 1 (2000): 286–93. http://dx.doi.org/10.1182/blood.v95.1.286.

Full text

Abstract:

Abstract The Wilms tumor (WT1) gene has been reported to be preferentially expressed in acute leukemia cells, regardless of leukemia subtype and chronic myelogenous leukemia cells in blast crisis, but not in normal cells. This finding suggests strongly that WT1 protein is a potential target of immunotherapy for human leukemia. In this study, we established a CD8+ cytotoxic T-lymphocyte (CTL) clone directed against a WT1-derived peptide and examined its immunologic actions on leukemia cells. A CD8+ CTL clone, designated TAK-1, which lysed autologous cells loaded with a WT1-derived 9-mer peptide

APA, Harvard, Vancouver, ISO, and other styles

9

Ohminami, Hideki, Masaki Yasukawa, and Shigeru Fujita. "HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide." Blood 95, no. 1 (2000): 286–93. http://dx.doi.org/10.1182/blood.v95.1.286.001k48_286_293.

Full text

Abstract:

The Wilms tumor (WT1) gene has been reported to be preferentially expressed in acute leukemia cells, regardless of leukemia subtype and chronic myelogenous leukemia cells in blast crisis, but not in normal cells. This finding suggests strongly that WT1 protein is a potential target of immunotherapy for human leukemia. In this study, we established a CD8+ cytotoxic T-lymphocyte (CTL) clone directed against a WT1-derived peptide and examined its immunologic actions on leukemia cells. A CD8+ CTL clone, designated TAK-1, which lysed autologous cells loaded with a WT1-derived 9-mer peptide consisti

APA, Harvard, Vancouver, ISO, and other styles

10

Mitchell, Malcolm S., Denise Darrah, David Yeung, et al. "Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope." Journal of Clinical Oncology 20, no. 4 (2002): 1075–86. http://dx.doi.org/10.1200/jco.2002.20.4.1075.

Full text

Abstract:

PURPOSE: To study distribution and toxicity of cytolytic T lymphocytes (CTLs) against a single melanoma epitope. PATIENTS AND METHODS: CD8+ T cells obtained by leukapheresis from 10 patients with disseminated HLA-A2.1+, tyrosinase-positive melanomas were immunized in vitro against tyrosinase369-377 (YMNGTMSQV). Drosophila cells transduced with HLA-A2.1, CD80, and CD54 (intracellular adhesion molecule-1) were used for priming, followed by two rounds of immunization with mononuclear cells as antigen-presenting cells. 1 × 108 CTL were infused intravenously (IV) on day 1. CTL frequency was measure

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "CD8-Positive T-Lymphocytes Immunotherapy"

1

Hjorth, Maria. "Immunological profile and aspects of immunotherapy in type 1 diabetes." Doctoral thesis, Linköping : Department of Clinical and Experimental Medicine, Linköping University, 2010. http://www2.bibl.liu.se/liupubl/disp/disp2010/med1161s.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dossett, Michelle Leigh. "Generation and expression of high affinity, tumor antigen-specific mouse and human T cell receptors to genetically modify CD8⁺ T cells for adoptive immunotherapy of cancer /." Thesis, Connect to this title online; UW restricted, 2006. http://hdl.handle.net/1773/8316.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!